Should the routinary determination of plasmatic fibrinogen as vascular risk indicative parameter be included in the metabolic syndrome patient?

Autor:	I. García-Caravaca, J. S. Luque-Martin, M. J. Ferreras-Duarte, J. J. Sánchez-Luque, M. V. Zunzunegui-Pastor, F. M. Gómez-Trujillo, C. Ortiz-Garcıéa
Rok vydání:	2001
Předmět:	medicine.medical_specialty business.industry Hip region Primary health care Vascular risk Fibrinogen medicine.disease MICROBIOLOGY PROCEDURES Endocrinology Diabetes mellitus Internal medicine Internal Medicine medicine Symptom onset Metabolic syndrome business medicine.drug
Zdroj:	American Journal of Hypertension. 14:A60-A61
ISSN:	0895-7061
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::cb9c0a17ec12ff34f3ced1c504822c7e https://doi.org/10.1016/s0895-7061(01)01633-8 Zobrazit plný text záznamu